On Monday, Johnson & Johnson (NYSE: JNJ) received approval in Europe for Zytiga as a pre-chemo treatment for prostate cancer. With Dendreon's (NASDAQ: DNDN) drug Provenge not approved in Europe yet, should investors be concerned about its ability to gain traction on the continent? Watch the following video and find out.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.